How could internal combustion engines help drive decarbonisation?

​
July 22, 2021

Last week, the UK Government announced that sales of new petrol and diesel heavy goods vehicles (HGVs) will be banned by 2040. The UK's Road Haulage Association supports the aim, but in a press release they say the proposal is unrealistic because alternatives don't yet exist.

What's the problem?

Many car companies are, of course, investing heavily in alternatives to petrol and diesel engines, and several electric vehicles (EVs) are already on sale. Some are battery electric vehicles (BEVs), which derive all their electric power from onboard battery packs. Others are fuel cell electric vehicles (FCEVs), which use fuel cells for onboard generation of electricity but often still have a sizeable battery to store it.

The trouble is that these technologies are unsuitable for heavy-duty machines like HGVs. Recharging a BEV can take hours. However, HGVs tend to travel for long periods, meaning there is less time available to recharge. Add the need for HGVs to have higher battery capacities due to their greater weight and journey lengths, and the problem is compounded. FCEVs can be refuelled in a comparable time to diesel-fuelled vehicles, but fuel cell technology remains very expensive. With both BEVs and FCEVs, there are also challenges around sourcing materials for batteries, and how to handle them at the end of their lives.

These are issues shared by manufacturers of heavy construction and agricultural equipment, such as JCB.

In a fascinating episode of Harry's Garage on YouTube last week, JCB's Chairman, Lord Bamford, highlighted that owners of heavy machinery want it to work long shifts to get maximum return on investment. For a mini excavator, that could be 4-5 hours per day, for a backhoe loader it could be 8 hours, and for larger machines it could be 16 hours over a double-shift. HGVs work for similarly long shifts.

JCB have a range of small BEVs for which the technology is appropriate because the batteries can power the machines for their relatively short shifts before needing a recharge. However, the technology isn't as suitable for harder-working equipment, since the necessary recharging would interrupt operations too much.

Weight and cost are also issues. JCB's experience is that battery costs aren't looking to reduce any time soon. Moreover, were a 20-tonne excavator to be converted to a BEV, its weight would increase by over 40%, so many components would also have to be upgraded to deal with the additional load. The result is a machine that would cost double the diesel-powered equivalent yet be unable to work equivalent shifts. Obviously, this would be unattractive to customers.

They are also exploring FCEVs, but indications are that they would be an expensive solution. Apparently, whereas the price of a 20-tonne diesel-powered JCB excavator is about £130k, a FCEV equivalent would be nearly £300k.

What's the solution?

JCB's solution is an internal combustion engine (ICE), albeit one that runs on hydrogen.

"It's not the combustion engine that's the problem, it's the fossil fuels" – Lord Bamford

Lord Bamford is of the view that there is a great future for ICEs. Indeed, they are highly reliable, relatively simple, cheap to manufacture, there are well-established supply chains for components, and they are well understood by manufacturers, service centres and many customers.

The concept of a hydrogen ICE has been around a long time. Indeed, the world's first ICE-powered automobile, at the beginning of the 19th century, ran on hydrogen.

JCB's hydrogen engine was unveiled in May, as reported in this Autocar article. The design, which first ran on a dyno in December, is based closely on their existing diesel engine architecture. In the Harry's Garage video, Paul McCarthy (Chief Engineer, JCB Power Systems) explains that the engine shares the same block as JCB's standard 4.8L diesel unit, but has a new cylinder head to accommodate the move to spark ignition.

Challenges overcome

A concern with hydrogen ICEs is that, while they do not emit CO2 (other than potentially a negligible amount from burning any engine oil in the cylinder), they can emit NOx generated from nitrogen and oxygen in incoming air. Hydrogen engines can run very lean, reducing the cylinder temperature and therefore the amount of NOx generated, but running lean reduces flame velocity and therefore power, so a balance needs to be struck.

Engine timing also needs consideration. Hydrogen's high diffusivity means a more uniform fuel-air mixture can be achieved in the cylinder, providing more complete combustion and efficiency, but there's potential for it to pass through intake valves before they are fully closed, resulting in backfiring.

Nevertheless, JCB seem to have overcome these issues and produced a viable ultra-low emission ICE that still delivers the required performance, with the low-end torque demanded by customers, while running a suitably lean mixture. In the Autocar article, it is also commented that:

"...the ‘raw' exhaust from the prototype engine contains less NOx than a diesel, even with the latest after-treatment that cuts diesel pollutants by 98%."

Lord Bamford says the design is still in its infancy, and it will be a zero-emission engine.

Importantly, the cost to JCB's customers will be only slightly higher than that of their diesel-powered equivalent machines. Weight and packaging will also be very similar – the hydrogen tanks will locate where the diesel tanks are at present – so there is no need to modify numerous other components. Also, and key to attracting customers, work cycles needn't change; the tanks can be filled in minutes and supply enough fuel to complete a full day's shift.

Challenges remaining

The remaining hurdles relate primarily to generating and storing hydrogen, but even these appear relatively surmountable.

Hydrogen can be produced by electrolysis of water. Siemens have technology relating to green hydrogen production using wind turbines to power electrolyzers, and Ryze Hydrogen, of which Lord Bamford's son Jo Bamford is Executive Chairman, is building the UK's first network of green hydrogen production plants. They also offer storage and distribution.

For the UK at least, there should be ample renewable energy available to power electrolyzers. At a recent conference I asked Dale Vince, founder of green energy company Ecotricity, whether it is possible for the UK to generate all its required electricity from the sun, wind and sea, and it was pleasing to hear that the answer is "yes, many times over". Apparently, solar alone could generate 8x the requirement, before considering land-based windfarms and offshore technologies.

Can JCB leverage IP?

There will be much interest in this technology, so it will be interesting to see whether JCB can leverage intellectual property (IP) in their work.

Although the broad concept of a hydrogen ICE has been known for 200+ years, the team at JCB will have devised solutions to numerous technical problems in designing a product that suits today's world. Some of these could be patentable, meaning they could get monopoly rights on them for up to 20 years. These rights could be used to prevent other companies from using the technology, or they could be licensed-out to permit use of the technology in return for payment of royalties.

The market for licensing could be substantial. In principle, the technology could be used by companies making other heavy-duty machines and vehicles, such as JCB's competitors in the construction and agricultural industries, as well as manufacturers of HGVs, buses and coaches. Moreover, it could be retrofitted to some existing machines, avoiding the need for scrappage and replacement with newly designed and manufactured ones – itself an environmental benefit. As such, so long as the claims of any patent rights cover retrofitting, further potential licensing revenue streams could exist.

Aside from licensing, JCB might be able to use the UK's Patent Box scheme to benefit from a reduced 10% corporate tax rate on profits from patented products, as explained on our Patentise website.

At this stage, it is not possible to see whether JCB have filed any patent applications from this project. Patent applications are, by default, published 18 months after being submitted to the patent office. As the project is about a year old, we will likely need to wait at least six months before any publications are made.

Freedom to operate

It is worth bearing in mind that JCB would be free to commercialize their new technology only if doing so wouldn't infringe third parties' patent rights.

Others are investigating hydrogen ICEs and might have filed patent applications of their own. For example, just last week, Cummins announced they have begun testing a hydrogen engine, and the week before AVL announced they are working with Westport Fuel Systems and TUPY to develop a hydrogen ICE for heavy goods transportation with first results expected by early next year. Ricardo also recently announced they are researching hydrogen ICEs.

If a third party owns IP rights that cover JCB's planned commercialization, aside from agreeing to pay royalties to take out a licence, JCB might be able to use to the third party's technology through cross-licensing of both sides' rights.

What about cars?

A challenge with smaller vehicles is accommodating the fuel tanks without impacting on passenger and luggage space. Hydrogen ICEs are less efficient than hydrogen fuel cells, so more space is needed for fuel storage for a given range.

BMW unveiled their Hydrogen 7 bivalent car fifteen years ago, but it returned very low mpg. Toyota clearly think this is still an area worth exploring, as shown by their recent demonstration of a hydrogen-powered Corolla with a modified GR Yaris ICE. Moreover, in an interview last Friday, Ross Brawn suggested that hydrogen could be the route to help F1 become carbon neutral while keeping the familiar noise.

With so much brain power now being directed at this technology, one suspects that a feasible small vehicle with a hydrogen ICE could materialise. If JCB or their competitors obtain IP rights that are also relevant to this large market, they could prove very lucrative indeed.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​